Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0184 has been discontinued.
View all Non-selective Ionotropic Glutamate products.Broad spectrum antagonist at ionotropic glutamate receptors.
M. Wt | 190.16 |
Storage | Store at RT |
CAS Number | 1204-75-7 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Erez et al (1985) Anticonvulsant properties of 3-hydroxy-2-quinoxalinecarboxylic acid, a newly found antagonist of excitatory amino acids. Eur.J.Pharmacol. 110 31 PMID: 2861099
Frey et al (1988) 6,7-Dichloro-3-hydroxy-2-quinoxalinecarboxylic acid is a relatively potent antagonist at NMDA and kainate receptors. Neurosci.Lett. 91 194 PMID: 2847085
Keywords: 3-Hydroxy-2-quinoxalinecarboxylic acid, 3-Hydroxy-2-quinoxalinecarboxylic acid supplier, Non-selective, Ionotropic, Glutamate, 0184, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for 3-Hydroxy-2-quinoxalinecarboxylic acid.
There are currently no reviews for this product. Be the first to review 3-Hydroxy-2-quinoxalinecarboxylic acid and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.